GT199900063A - Mesilato de n-(3-etinilfenilamino) -6, 7 -bis (2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado. - Google Patents

Mesilato de n-(3-etinilfenilamino) -6, 7 -bis (2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado.

Info

Publication number
GT199900063A
GT199900063A GT199900063A GT199900063A GT199900063A GT 199900063 A GT199900063 A GT 199900063A GT 199900063 A GT199900063 A GT 199900063A GT 199900063 A GT199900063 A GT 199900063A GT 199900063 A GT199900063 A GT 199900063A
Authority
GT
Guatemala
Prior art keywords
mesylate
metoxyetoxy
anhydred
ethylphenylamine
monohydrated
Prior art date
Application number
GT199900063A
Other languages
English (en)
Inventor
Douglas John Meldrun Allenn
Timoth Norris
Jeffrey William Raggon
Dinos Paul Santafianos
Ravi Mysore Shanker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900063A publication Critical patent/GT199900063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LAS FORMAS ANHIDRAS E HIDRATADAS DEL MESILATO DE N(3ETILFENIL)6, 7BIS(2METOXIETOXI)4QUINAZOLINA, LAS FORMAS DISTINTAS EN QUE EXISTE EL COMPUESTO SON TRES: A,B Y C Y TAMBIEN COMO MONOHIDRATO, SE MUESTRAN EN EL ESQUEMA INSCRITO ABAJO. LA INVENCION SE REFIERE A LA OBTENCION DE ESTAS FORMAS SEPARADAS SEGUN LA SECUENCIA DE ETAPAS DURANTE EL PROCESO DE SINTESIS Y LA TECNICA DE CRISTALIZACION TERMINAL. LA INVENCION ESTABLECE TAMBIEN: LAS CARACTERISTICAS CRISTALOGRAFICAS DE ESTAS TRES FORMAS OBTENIDAS, SUS COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS DE TRATAMIENTO PARA ALTERACIONES HIPERPROLIFERATIVAS, COMO EL CANCER MEDIANTE LA ADMINISTRACION DEL COMPUESTO EN CUESTION.
GT199900063A 1998-04-29 1999-04-29 Mesilato de n-(3-etinilfenilamino) -6, 7 -bis (2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado. GT199900063A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (1)

Publication Number Publication Date
GT199900063A true GT199900063A (es) 2000-10-20

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900063A GT199900063A (es) 1998-04-29 1999-04-29 Mesilato de n-(3-etinilfenilamino) -6, 7 -bis (2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado.

Country Status (42)

Country Link
EP (1) EP1076652B1 (es)
JP (1) JP4652569B2 (es)
KR (1) KR100668412B1 (es)
CN (2) CN1298396A (es)
AP (1) AP1252A (es)
AR (1) AR018201A1 (es)
AT (1) ATE295839T1 (es)
AU (1) AU759691C (es)
BR (1) BR9910025A (es)
CA (1) CA2330447C (es)
CO (1) CO5060467A1 (es)
CZ (1) CZ298230B6 (es)
DE (1) DE69925366T2 (es)
DZ (1) DZ2777A1 (es)
EA (1) EA002836B1 (es)
EG (1) EG24000A (es)
ES (1) ES2238825T3 (es)
GT (1) GT199900063A (es)
HK (1) HK1037180A1 (es)
HN (1) HN1999000057A (es)
HU (1) HU227569B1 (es)
ID (1) ID27198A (es)
IL (1) IL139172A0 (es)
MA (1) MA26624A1 (es)
ME (1) MEP42008A (es)
MX (1) MXPA00010610A (es)
MY (1) MY136033A (es)
NO (1) NO317301B1 (es)
NZ (1) NZ508154A (es)
OA (1) OA11769A (es)
PA (1) PA8471001A1 (es)
PE (1) PE20000441A1 (es)
PL (1) PL196940B1 (es)
RS (1) RS50081B (es)
SA (1) SA99200216B1 (es)
TN (1) TNSN99079A1 (es)
TR (1) TR200003166T2 (es)
TW (1) TWI248437B (es)
UA (1) UA60363C2 (es)
UY (1) UY26099A1 (es)
WO (1) WO1999055683A1 (es)
ZA (1) ZA992972B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
KR101126560B1 (ko) 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
ES2293251T3 (es) 2003-06-10 2008-03-16 F. Hoffmann-La Roche Ag Derivados de 1,3,4-triaza-fenaleno y 1,3,4,6-tetraazafenaleno.
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2565721C (en) 2004-05-06 2015-10-06 Bioresponse, L.L.C. Diindolymethane formulations for the treatment of leiomyomas
ATE497762T1 (de) 2004-12-30 2011-02-15 Bioresponse Llc Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
US8586621B2 (en) 2006-10-27 2013-11-19 Michael A. Zeligs Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
CA2682013C (en) * 2007-04-04 2015-06-30 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
EP2213665A1 (en) 2007-08-17 2010-08-04 Hetero Drugs Limited Erlotinib hydrochloride
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
DK0817775T3 (da) * 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
HN1999000057A (es) 1999-09-29
EA002836B1 (ru) 2002-10-31
EG24000A (en) 2008-03-19
HK1037180A1 (en) 2002-02-01
MEP42008A (en) 2011-02-10
NZ508154A (en) 2003-07-25
CZ298230B6 (cs) 2007-08-01
CA2330447C (en) 2009-06-30
MXPA00010610A (es) 2002-07-02
CO5060467A1 (es) 2001-07-30
EA200001112A1 (ru) 2001-04-23
NO20005453D0 (no) 2000-10-27
NO20005453L (no) 2000-12-20
HUP0101818A1 (hu) 2002-03-28
ES2238825T3 (es) 2005-09-01
TNSN99079A1 (fr) 2005-11-10
MY136033A (en) 2008-07-31
CN1298396A (zh) 2001-06-06
RS50081B (sr) 2009-01-22
TWI248437B (en) 2006-02-01
PL343766A1 (en) 2001-09-10
JP4652569B2 (ja) 2011-03-16
KR20010078710A (ko) 2001-08-21
AR018201A1 (es) 2001-10-31
AP9901523A0 (en) 1999-06-30
BR9910025A (pt) 2000-12-26
NO317301B1 (no) 2004-10-04
PL196940B1 (pl) 2008-02-29
AU759691C (en) 2004-04-29
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
JP2002513009A (ja) 2002-05-08
PA8471001A1 (es) 2000-09-29
ID27198A (id) 2001-03-08
EP1076652A1 (en) 2001-02-21
SA99200216B1 (ar) 2006-06-04
AU2850999A (en) 1999-11-16
ZA992972B (en) 2000-10-30
CZ20003974A3 (en) 2001-05-16
EP1076652B1 (en) 2005-05-18
AU759691B2 (en) 2003-04-17
ATE295839T1 (de) 2005-06-15
IL139172A0 (en) 2001-11-25
CA2330447A1 (en) 1999-11-04
KR100668412B1 (ko) 2007-01-12
HU227569B1 (en) 2011-08-29
AP1252A (en) 2004-02-25
OA11769A (en) 2005-07-25
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
WO1999055683A1 (en) 1999-11-04
DE69925366D1 (de) 2005-06-23
PE20000441A1 (es) 2000-05-23
MA26624A1 (fr) 2004-12-20
TR200003166T2 (tr) 2001-02-21
HUP0101818A3 (en) 2002-05-28
UA60363C2 (uk) 2003-10-15
CN101219999A (zh) 2008-07-16

Similar Documents

Publication Publication Date Title
GT199900063A (es) Mesilato de n-(3-etinilfenilamino) -6, 7 -bis (2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado.
CY1106405T1 (el) Παραγωγα κουιναζολινης
ECSP056019A (es) 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune
UY28516A1 (es) Derivados de quinazolina
ECSP045003A (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos.
TW200519104A (en) Quinazoline derivatives
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
AR033383A1 (es) Derivados de acridina, procedimiento para prepararlos, el uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
ATE353888T1 (de) Chinazolinderivate
CY1108129T1 (el) Παραγωγα 4-αμινο-6-φαινυλ-πυρρολο[2,3-δ]πυριμιδινης
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
UY28519A1 (es) Derivados de quinazolina
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
CO2023010694A2 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
DE60323510D1 (de) Implantat für den transport und die freigabe von pharmakologisch aktiven substanzen
HN2002000334A (es) Procedimiento para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
AR024411A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas.
ECSP024377A (es) Derivados de benzo (g) quinolina
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
HRP20020238A2 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
AR022740A1 (es) Analogos opticamente puros de la camptotecina, composiciones farmaceuticas que los contienen y uso de los mismos como agentes antitumorales
AR029755A1 (es) Ditiepino (6,5-b) piridinas,analogos y drogas blandas de dichas piridinas, composicion farmaceutica que los comprende, usos de dosis de la composicion farmaceutica para la preparacion de medicamentos, aparato para la administracion de la composicion farmaceutica y procesos para la preparacion de dic